Table 2.
Leading Cancer Sites for American Indians/Alaska Nativesa compared to Non-Hispanic Whites for the United States, Females, All ages, PRCDA Counties, US, 2010–2015
| Overall | Northern Plains | Alaska | Southern Plains | Pacific Coast | East | Southwest | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cancer Site | Rankb AI/AN (W) | AI/AN(W) Ratec | RRd | Rankb AI/AN (W) | AI/AN(W) Ratec | RRd | Rankb AI/AN (W) | AI/AN(W) Ratec | RRd | Rankb AI/AN (W) | AI/AN(W) Ratec | RRd | Rankb AI/AN (W) | AI/AN(W) Ratec | RRd | Rankb AI/AN (W) | AI/AN(W) Ratec | RRd | Rankb AI/AN (W) | AI/AN (W) Ratec | RRd |
| Female Breast | 1(1) | 112.5 (129.9) | 0.87e | 1(1) | 128.4 (122.7) | 1.05 | 1(1) | 156.2 (124.1) | 1.26e | 1(1) | 151.1 (116.1) | 1.30e | 1(1) | 124.3 (133.9) | 0.93e | 1(1) | 83.6 (136.4) | 0.61e | 1(1) | 68.3 (120.6) | 0.57e |
| Lung and Bronchus | 2(2) | 58.6(55.4) | 1.06e | 2(2) | 104.0 (53.9) | 1.93e | 3(2) | 73.5(51.8) | 1.42e | 2(2) | 87.3(56.9) | 1.53e | 2(2) | 63.0(52.7) | 1.20e | 2(2) | 42.0(61.5) | 0.68e | 6(2) | 15.9(48.7) | 0.33e |
| Colon and Rectum | 3(3) | 45.4(33.1) | 1.37e | 3(3) | 51.3 (33.9) | 1.51e | 2(3) | 92.8(32.3) | 2.87e | 3(3) | 57.9(34.8) | 1.66e | 3(3) | 44.6(32.5) | 1.37e | 3(3) | 30.2(34) | 0.89 | 2(3) | 28.8(30.6) | 0.94 |
| Corpus and Uterus, NOS | 4(4) | 26.7(25.9) | 1.03 | 4(4) | 25.2 (28.4) | 0.89 | 6(4) | 18.2(26.5) | 0.68e | 4(4) | 29.4(21.5) | 1.37e | 4(5) | 29.3(25.9) | 1.13 | 4(4) | 19.0(27.3) | 0.70e | 3(5) | 27.7(22.1) | 1.25e |
| Kidney and Renal Pelvis | 5(11) | 20.0(10.8) | 1.85e | 5(9) | 23.4(11.1) | 2.11e | 5(10) | 21.6(10.9) | 1.98e | 5(8) | 27.9(12.6) | 2.21e | 7(11) | 15.5(10.3) | 1.51e | 5(12) | 12.6(11.3) | 1.12 | 5(11) | 17.1(9.5) | 1.81e |
| Thyroid | 6(5) | 17.9(22.5) | 0.80e | 7(6) | 16.0(19.3) | 0.83e | 4(6) | 24.6(15.6) | 1.58e | 6(5) | 21.0(18.9) | 1.1 | 5(6) | 18.3(20.1) | 0.91 | 7(5) | 9.2(25.7) | 0.36e | 4(4) | 17.3(25.8) | 0.67e |
| Non-Hodgkin Lymphoma | 7(7) | 15.0(15.9) | 0.95 | 6(7) | 16.4(16.6) | 0.99 | 8(7) | 14.5(14.4) | 1.01 | 7(7) | 19.5(14.6) | 1.34e | 6(7) | 17.1(15.7) | 1.09 | 6(7) | 10.2(16.8) | 0.60e | 9(7) | 11.1(13.7) | 0.81e |
| Ovary | 8(8) | 12.6(11.8) | 1.06 | 8(8) | 12.8(11.1) | 1.15 | 12(8) | 8.8(12.6) | 0.7 | 9(9) | 15(11.5) | 1.30e | 10(8) | 10.7(12.2) | 0.88 | 15(8) | 6.3(12.0) | 0.52e | 7(8) | 14.4(11.4) | 1.26e |
| Pancreas | 9(10) | 11.6(10.8) | 1.07 | 10(11) | 12.5(10.6) | 1.18 | 9(9) | 13.8(11.1) | 1.25 | 8(11) | 15.7(10.0) | 1.58e | 13(10) | 10.2(10.7) | 0.95 | 10(10) | 7.2(11.4) | 0.63e | 10(9) | 9.6(9.8) | 0.99 |
| Cervix | 10(14) | 11.2(6.6) | 1.69e | 9(14) | 12.7(6.2) | 2.04e | 11(13) | 10.4(6.3) | 1.65e | 10(12) | 13.9(8.4) | 1.65e | 8(14) | 15.1(6.9) | 2.19e | 9(14) | 7.8(6.4) | 1.21 | 13(13) | 7.2(6.3) | 1.14 |
| Liver and Intrahepatic Bile Duct | 11(17) | 10.5(3.4) | 3.08e | 12(18) | 10.5(3.1) | 3.43e | 16(17) | 6.5(3.2) | 2.02e | 12(17) | 9.5(3.5) | 2.71e | 9(17) | 10.8(3.7) | 2.90e | 11(18) | 7.2(3.3) | 2.20e | 8(17) | 12.5(3.4) | 3.71e |
| Leukemias | 12(9) | 10.0(11.0) | 0.91e | 11(10) | 12.2(11.0) | 1.11 | 14(12) | 8.0(10.2) | 0.78 | 11(10) | 13.2(10.8) | 1.23e | 11(9) | 10.5(10.9) | 0.97 | 12(9) | 6.9(11.8) | 0.59e | 12(10) | 7.6(9.8) | 0.77e |
| Stomach | 13(18) | 7.5(3.3) | 2.29e | 15(17) | 6.2(3.1) | 1.98e | 7(18) | 16.3(2.9) | 5.55e | 16(18) | 6.0(2.8) | 2.14e | 17(18) | 4.8(3.1) | 1.56e | 8(17) | 8.1(3.9) | 2.08e | 11(18) | 9.1(2.7) | 3.36e |
| Oral Cavity and Pharynx | 14(13) | 6.9(6.8) | 1.02 | 13(13) | 10.5(6.7) | 1.55e | 10(15) | 13.7(5.5) | 2.49e | 15(14) | 6.3(6.9) | 0.9 | 14(13) | 8.4(7.0) | 1.21 | 14(13) | 6.8(7.2) | 0.93 | 17(15) | 3.4(5.6) | 0.62e |
| Melanomas of the Skin | 15(6) | 6.7(22.4) | 0.30e | 19(5) | 3.8(20.2) | 0.19e | 15(5) | 7.4(16.0) | 0.46e | 13(6) | 9.1(15.4) | 0.59e | 12(4) | 10.3(26.8) | 0.38e | 13(6) | 6.8(22.3) | 0.31e | 16(6) | 4.0(18.8) | 0.21e |
Source: Cancer registries in the Centers for Disease Control and Prevention’s National Program of Cancer Registries (NPCR) and/or the National Cancer Institute’s Surveillance, Epidemiology and End Results Program (SEER)
PRCDA indicates Purchased/Referred Care Delivery Areas; AI/AN: American Indians/Alaska Natives; W: non-Hispanic white.
AI/AN race is reported by NPCR and SEER registries or through linkage with the IHS patient registration database. Includes only AI/AN of non-Hispanic origin.
Rank based on rates. AI/AN (white)
Rates are per 100,000 persons and are age-adjusted to the 2000 U.S. standard population (19 age groups - Census P25–1130).
Rate ratios (RR) are AI/AN versus White and are calculated in SEER*Stat prior to rounding of rates and may not equal RR calculated from rates presented in table.
Indicates RR is statistically significant (p<0.05).
Years of data and registries used: 1999–2015 (48 states): AK*, AL*, AZ*, CA*, CO*, CT*, DE, DC, FL*, GA, HI, IA*, ID*, IL, IN*, KS*, KY, LA*, MA*, MD, ME*, MI*, MN*, MO, MT*, ND* NE*, NH, NJ, NM*, NV*, NY*, NC*, OH, OK*, OR*, PA*, RI*, SC*, TX*, TN, UT*, VT, VA, WA*, WI*, WV, WY*; 2000–2015: AR, SD*; 2003–2015: MS*. *States with at least one county designated as PRCDA.
Percent regional coverage of AI/AN in PRCDA counties to AI/AN in all counties: Northern Plains=54.2%; Alaska=100%; Southern Plains=56.5%; Southwest=83.8%; Pacific Coast=60.2%; East=16.4%; Total US=53.0%.